Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Long intergenic non-coding RNA DIO3OS promotes osteosarcoma metastasis via activation of the TGF-β signaling pathway: a potential diagnostic and immunotherapeutic target for osteosarcoma

Fig. 5

Testing and validating DIO3OS as a biomarker for the diagnosis of osteosarcoma. A DIO3OS expression in osteosarcoma and various subtypes of sarcoma (FN, LN, MN, NST, NOS, and SN) in test cohort. B–G The area under the ROC curve (AUC) in the TARGET and TCGA sets assesses the differential diagnostic performance of DIO3OS between osteosarcoma and other subtypes of sarcoma. H DIO3OS expression in osteosarcoma and various subtypes of sarcoma (LN, MN, NST, and SN) in validate cohort. I–L The area under the ROC curve (AUC) in the validate cohort assesses the differential diagnostic performance of DIO3OS between osteosarcoma and other subtypes of sarcoma. M In validate cohort, the expression level of DIO3OS between metastasis and non-metastasis groups. N The effect of metastasis on the prognosis of osteosarcoma overall survival (OS) is statistically significant in validate cohort. O The effect of high DIO3OS expression on the prognosis of osteosarcoma overall survival (OS) is statistically significant in validate cohort. P Time-dependent ROC curves, 1-Year (AUC = 0.747), 3-Year (AUC = 0.872), 5-Year (AUC = 0.960) in validate cohort. P-value of less than 0.05 is considered statistically significant (ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us